Blueprint Medicines
Developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases.
Launch date
Employees
Market cap
AUD8.2b
Enterprise valuation
AUD7.8b (Public information from Sep 2024)
Share price
$89.33 BPMC
Cambridge Massachusetts (HQ)
Authorizing premium user...